Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Foamix Pharmaceuticals Ltd. | exhibit_32-2.htm |
| EX-31.2 - EXHIBIT 31.2 - Foamix Pharmaceuticals Ltd. | exhibit_31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Foamix Pharmaceuticals Ltd. | exhibit_31-1.htm |
| EX-23.1 - EXHIBIT 23.1 - Foamix Pharmaceuticals Ltd. | exhibit_23-1.htm |
| EX-10.8 - EXHIBIT 10.8 - Foamix Pharmaceuticals Ltd. | exhibit_10-8.htm |
| EX-10.7 - EXHIBIT 10.7 - Foamix Pharmaceuticals Ltd. | exhibit_10-7.htm |
| EX-10.6 - EXHIBIT 10.6 - Foamix Pharmaceuticals Ltd. | exhibit_10-6.htm |
| 10-K/A - 10-K/A - Foamix Pharmaceuticals Ltd. | zk1821314.htm |
Exhibit 32.1
CERTIFICATION OF CEO PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Foamix Pharmaceuticals Ltd. (the "Company") for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), David Domzalski, as Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: March 1, 2018
|
By:
|
/s/ David Domzalski
|
|
|
David Domzalski
Chief Executive Officer
|
This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.